Security Snapshot

Chugai Pharmaceutical Co Ltd - Common Stock (CHGCY) Institutional Ownership

CUSIP: 171269103

13F Institutional Holders and Ownership History from Q1 2017 to Q2 2026

Latest Period

Q1 2026

Institutions Reporting

13

Shares (Excl. Options)

169,265

Price

$27.52

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,735
Value change
+$50,605
Number of holders
13
Issuer context Names, identifiers, and filing context for this profile. 1 identity field
SEC-reported price per share
$22.88
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors

Key facts

  • CHGCY - Chugai Pharmaceutical Co Ltd - Common Stock is tracked under CUSIP 171269103.
  • 13 institutions reported positions in Q1 2026.
  • Schedule 13D/13G significant owner rows are not currently available.

Change

  • Holder count moved from 13 to 6 between Q1 2026 and Q2 2026.
  • SEC-reported value moved from $4,641,648 to $2,477,107.

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 13 institutions filings for Q1 2026.

Open SEC evidence

Security key

171269103

Latest holder period

Q1 2026

13F holders

13

13D/G owners

0

CIK / CUSIP context first

As of 31 Mar 2026, 13 institutional investors reported holding 169,265 shares of Chugai Pharmaceutical Co Ltd - Common Stock (CHGCY).

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
38
Latest
Q1 2026
Rows shown
1-25 of 38
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q2 107,207 $2,477,107 -$348,542 $23.08 6
2026 Q1 169,265 $4,641,648 +$50,605 $27.52 13
2025 Q4 167,530 $4,402,782 +$708,585 $26.27 13
2025 Q3 140,494 $3,094,381 -$860,539 $22.11 8
2025 Q2 177,534 $4,626,291 +$61,685 $26.07 12
2025 Q1 175,170 $3,983,186 +$404,396 $22.74 11
2024 Q4 157,400 $3,478,355 -$359,564 $21.97 7
2024 Q3 172,761 $4,171,984 -$3,911,046 $24.09 8
2024 Q2 323,971 $5,756,959 +$525,080 $17.77 6
2024 Q1 293,340 $5,611,597 +$200,772 $19.13 9
2023 Q4 282,883 $5,326,910 -$320,150 $18.85 8
2023 Q3 294,427 $4,531,526 -$295,856 $15.39 6
2023 Q2 313,684 $4,464,886 -$3,136,050 $14.19 6
2023 Q1 571,378 $7,017,491 +$1,297,008 $12.28 6
2022 Q4 465,771 $5,902,444 +$2,700,566 $12.67 4
2022 Q3 252,565 $3,143,000 -$4,016,910 $12.49 3
2022 Q2 286,130 $3,654,000 +$374,044 $12.77 3
2022 Q1 472,111 $7,871,000 +$875,313 $16.71 5
2021 Q4 419,593 $6,861,000 -$1,463,761 $16.36 5
2021 Q3 484,112 $8,889,000 +$4,881,247 $18.36 9
2021 Q2 218,255 $4,343,000 -$26,864,303 $19.91 5
2021 Q1 1,541,688 $31,294,011 -$5,652,914 $20.29 9
2020 Q4 1,738,494 $46,266,416 +$4,305,264 $26.60 10
2020 Q3 1,576,618 $35,290,824 +$32,278,993 $22.40 9
2020 Q2 125,955 $41,101,157 +$10,874,948 $326.09 9
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .